Loading...
Market
Overall market share trend for Humira and its biosimilars by end of 2024
5
Resolution / Starting Odds
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Industry market share reports from pharmaceutical analysis firms
Story
CVS Health Switch to Hyrimoz Biosimilar Captures 36% Market Share
Apr 16, 2024, 02:25 PM
Following a strategic shift by CVS Health, the prescription of biosimilar versions of Humira, notably Hyrimoz, has seen a significant surge. CVS Health, through its PBM Caremark which covers approximately 30 million US patients, removed Humira from its formulary on April 1st and replaced it with Hyrimoz, marketed by CVS's subsidiary Cordavis. This change led to an increase in Hyrimoz prescriptions from 640 to 8300 in just one week, capturing a market share of 36% from just 5%. The market share for Hyrimoz notably increased, while other Humira biosimilars did not experience similar growth. Approximately half of the new prescriptions for Humira biosimilars were for Hyrimoz, despite there being nine different biosimilars available in the U.S. market.
View original story
Similar markets
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
No change • 25%
Increase by up to 20% • 25%
Increase by 21% to 40% • 25%
Increase more than 40% • 25%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
0-2 competitors • 25%
3-5 competitors • 25%
6-8 competitors • 25%
More than 8 competitors • 25%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%
Equal market share between Biocon and Biogen • 34%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Top 10% • 25%
Top 25% • 25%
Top 50% • 25%
Below 50% • 25%
Increase • 33%
No significant change • 33%
Decrease • 33%
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%